This study focuses on adults with HIV-1 who have their virus controlled by daily pills. It will test if switching to a new injectable treatment works as well as the current injectable drugs. **Lenacapavir (LEN)**, **Teropavimab (TAB)**, and **Zinlirvimab (ZAB)** are new long-acting injections. They are being compared to **Cabotegravir (CAB)** and **Rilpivirine (RPV)**, which are already used. Participants must have undetectable virus levels and have been stable on their medication for at least 6 months. **Key Points:** - The study lasts **52 weeks** with regular check-ups. - Participants will receive **injections every 8 weeks**. - **Eligibility** requires stable HIV-1 control and no resistance to the drugs being tested. This study could help determine if the new injections are a better option for people living with HIV-1. Participants must ensure they meet the study's criteria and be comfortable with the injection schedule.